Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000081125 | SCV000113033 | uncertain significance | not provided | 2016-05-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000543899 | SCV000640725 | benign | Nemaline myopathy 2 | 2024-01-11 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000081125 | SCV001989942 | uncertain significance | not provided | 2024-06-14 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: Olimpia_2023) |
Natera, |
RCV000543899 | SCV001456461 | uncertain significance | Nemaline myopathy 2 | 2020-01-24 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004549518 | SCV004793953 | uncertain significance | NEB-related disorder | 2023-11-10 | no assertion criteria provided | clinical testing | The NEB c.23753C>T variant is predicted to result in the amino acid substitution p.Ser7918Leu. This variant has been reported with uncertain significance in the heterozygous state, along with variants in other genes, in an individual with myofibrillar myopathy (Case 1, Carbunar O, M Saporta, and S Gultekin. 2023. doi:10.17161/rrnmf.v4i2.18512). This variant is reported in 0.088% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/2-152362681-G-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |